A novel phosphodiesterase-5 Inhibitor: Yonkenafil modulates neurogenesis, gliosis to improve cognitive function and ameliorates amyloid burden in an APP/PS1 transgenic mice model

Mechanisms of Ageing and Development

Volumn 150, Issue , 2015, Pages 34-45

  Zhu, Lei ^a   Yang, Jing Yu ^a   Xue, Xue ^c   Dong, Ying Xu ^a   Miao, Feng Rong ^a   Wang, Yong Feng ^d   Xue, Hong ^a,b   Wu, Chun Fu ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c INSTITUTE OF BIOPHYSICS   (China)

^d Zhuhai Oxforston PharmTech Co Ltd ^*  (China)

Author keywords

Cognitive; Microglia; Neurogenesis; Yonkenafil; amyloid

Indexed keywords

AMYLOID BETA PROTEIN; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UNCLASSIFIED DRUG; YONKENAFIL; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN;

AMNESIA; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; GLIOSIS; HIPPOCAMPUS; MALE; MENTAL PERFORMANCE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; WORKING MEMORY; ALZHEIMER DISEASE; ANIMAL; BIOSYNTHESIS; COGNITION; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; MEMORY; METABOLISM;

MUS; MUS MUSCULUS;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; DISEASE MODELS, ANIMAL; GLIOSIS; HUMANS; MALE; MEMORY; MICE; MICE, TRANSGENIC; NEUROGENESIS; PHOSPHODIESTERASE 5 INHIBITORS;

EID: 84940391361     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2015.07.002     Document Type: Article

References (59)

1. Andric S.A., Janjic M.M., Stojkov N.J., Kostic T.S. Sildenafil treatment in vivo stimulates Leydig cell steroidogenesis via the cAMP/cGMP signaling pathway. Am. J. Physiol. Endocrinol. Metab. 2010, 299:E544-E550.
2. Balducci C., Forloni G. APP transgenic mice: their use and limitations. Neuromolecular Med. 2011, 13:117-137.
3. Bath K.G., Akins M.R., Lee F.S. BDNF control of adult SVZ neurogenesis. Dev. Psychobiol. 2012, 54:578-589.
4. Bornemann K.D., Wiederhold K.H., Pauli C., Ermini F., Stalder M., Schnell L., Sommer B., Jucker M., Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am. J. Pathol. 2001, 158:63-73.
5. Chen X., Wang N., Liu Y., Liu Y., Zhang T., Zhu L., Wang Y., Wu C., Yang J. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp. Neurol. 2014, 261C:267-277.
6. Chen X., Wang N., Liu Y., Liu Y., Zhang T., Zhu L., Wang Y., Wu C., Yang J. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp. Neurol. 2014, 261:267-277.
7. Chen X.M., Wang N.N., Zhang T.Y., Wang F., Wu C.F., Yang J.Y. Neuroprotection by sildenafil: neuronal networks potentiation in acute experimental stroke. CNS Neurosci. Ther. 2014, 20:40-49.
8. Chow V.W., Mattson M.P., Wong P.C., Gleichmann M. An overview of APP processing enzymes and products. Neuromolecular Med. 2009, 12:1-12.
9. Chuang T.T. Neurogenesis in mouse models of Alzheimer's disease. Biochim. Biophys. Acta 2010, 1802:872-880.
10. Combs C.K., Karlo J.C., Kao S.-C., Landreth G.E. β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 2001, 21:1179-1188.
11. Coraci I.S., Husemann J., Berman J.W., Hulette C., Dufour J.H., Campanella G.K., Luster A.D., Silverstein S.C., El Khoury J.B. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer's disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils. Am. J. Pathol. 2002, 160:101-112.
12. Cuadrado-Tejedor M., Hervias I., Ricobaraza A., Puerta E., Perez-Roldan J.M., Garcia-Barroso C., Franco R., Aguirre N., Garcia-Osta A. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. Br. J. Pharmacol. 2011, 164:2029-2041.
13. DAF , JFS , JSP , SHSD , JB , C , Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase The Journal of Biological Chemistry 273, 1998; 15559-15564.
14. Frank M., Longo T.Y., Youmei X., Massa A.S.M. Small molecule approaches for promoting neurogenesis. Curr. Alzheimer Res. 2006, 3:5-10.
15. Galasko D., Schmitt F., Thomas R., Jin S., Bennett D., Ferris S. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J. Int. Neuropsychol. Soc. 2005, 11:446-453.
16. Garcia-Barroso C., Ricobaraza A., Pascual-Lucas M., Unceta N., Rico A.J., Goicolea M.A., Salles J., Lanciego J.L., Oyarzabal J., Franco R., Cuadrado-Tejedor M., Garcia-Osta A. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology 2013, 64:114-123.
17. Garcia-Osta A., Cuadrado-Tejedor M., Garcia-Barroso C., Oyarzabal J., Franco R. Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem. Neurosci. 2012, 3:832-844.
18. Gouras G.K., Almeida C.G., Takahashi R.H. Intraneuronal abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 2005, 26:1235-1244.
19. Gratzner H.G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science 1982, 218:474-475.
20. Handattu S.P., Garber D.W., Monroe C.E., van Groen T., Kadish I., Nayyar G., Cao D., Palgunachari M.N., Li L., Anantharamaiah G.M. Oral apolipoprotein A-I mimetic peptide improves cognitive function and reduces amyloid burden in a mouse model of Alzheimer's disease. Neurobiol. Dis. 2009, 34:525-534.
21. Heneka M., Obanion M. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184:69-91.
22. Hooper N., Fraser C., Stone T.W. Effects of purine analogues on spontaneous alternation in mice. Psychopharmacology 1996, 123:250-257.
23. Hou Y., Aboukhatwa M.A., Lei D.L., Manaye K., Khan I., Luo Y. Anti-depressant natural flavonols modulate BDNF and beta amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology 2010, 58:911-920.
24. Jin F., Gong Q.-H., Xu Y.-S., Wang L.-N., Jin H., Li F., Li L.-S., Ma Y.-M., Shi J.-S. Icariin, a phoshphodiesterase-5 inhibitor, improves learning and memory in APP/PS1 transgenic mice by stimulation of NO/cGMP signalling. Int. J. Neuropsychopharmacol. 2014, 17:871-881.
25. Jin K., Galvan V., Xie L., Mao X.O., Gorostiza O.F., Bredesen D.E., Greenberg D.A. Enhanced neurogenesis in Alzheimer's disease transgenic (PDGF-APPSw,Ind) mice. Proc. Natl. Acad. Sci. U.S.A 2004, 101:13363-13367.
26. Kee N., Sivalingam S., Boonstra R., Wojtowicz J. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J. Neurosci. Methods 2002, 115:97-105.
27. Kee N., Sivalingam S., Boonstra R., Wojtowicz J.M. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J. Neurosci. Methods 2002, 115:97-105.
28. Leigh Holcome, Eileen M.N.G., Mcgowan, Xin Yu, Stan Benkovie, Paul Jantzen, Kristal Wright, Irene Saad, Ryan Mueller, Dave Morgan, Sunnny Sanders, Cindy Zehr, Kassandra O'campo, John Hardy, Cristian-mihail Prada, Steve Younkin, Karen Hsiao, Karen Duff Accelerated Alzheimer-type Phenotype in Transgenic Mice Carrying Both Mutant Amyloid Precursor Protein and Presenilin 1 Transgenes 1998, 4:97-100. Nature Publishing Group.
29. Mattson M.P. Pathways towards and Away from Alzheimer's Disease 2004, 430:631-639. Nature Publishing Group.
30. McGeer E.G., McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27:741-749.
31. Mori T., Koyama N., Arendash G.W., Horikoshi-Sakuraba Y., Tan J., Town T. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease. Glia 2010, 58:300-314.
32. Mu Y., Gage F.H. Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegener. 2011, 6:85.
33. Orejana L., Barros-Minones L., Jordan J., Cedazo-Minguez A., Tordera R.M., Aguirre N., Puerta E. Sildenafil Decreases BACE1 and Cathepsin B Levels and Reduces APP Amyloidogenic Processing in the SAMP8 Mouse. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 2015, 70:675-685.
34. Paris D., Town T., Mullan M. Novel strategies for opposing murine microglial activation. Neurosci. Lett. 2000, 278:5-8.
35. Paris D., Town T., Parker T., Humphrey J., Mullan M. β-Amyloid vasoactivity and proinflammation in microglia can be blocked by cGMP-elevating agents. Ann. N.Y. Acad. Sci. 2000, 903:446-450.
36. Prickaerts J., Van Staveren W., Şik A., Markerink-van Ittersum M., Niewöhner U., Van der Staay F., Blokland A., De Vente J. Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 2002, 113:351-361.
37. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 2003, 278:19777-19783.
38. Puzzo D., Loreto C., Giunta S., Musumeci G., Frasca G., Podda M.V., Arancio O., Palmeri A. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol. Aging 2014, 35:520-531.
39. Puzzo D., Staniszewski A., Deng S.X., Privitera L., Leznik E., Liu S., Zhang H., Feng Y., Palmeri A., Landry D.W., Arancio O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J. Neurosci. Off. J. Soc. Neurosci. 2009, 29:8075-8086.
40. Roof, R., Yabe, Y., Zaleska, M., 2010. Use of Ethological Rodent Behavior to Assess Efficacy of Potential Drugs for Alzheimer's Disease. AJ Spink FG, OE, Krips, LWS, Loijens, LPJJ Noldus, and PH Zimmerman, editor.
41. Rutten K., Vente J.D., Sik A., Ittersum M.M., Prickaerts J., Blokland A. The selective PDE5 inhibitor, sildenafil, improves object memory in Swiss mice and increases cGMP levels in hippocampal slices. Behav. Brain Res. 2005, 164:11-16.
42. Schmidt M.L., Robinson K.A., Lee V., Trojanowski J.Q. Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am. J. Pathol. 1995, 147:503.
43. Shetty M.S.R.A.K. Efficacy of doublecortin as a marker to analyse the absolute number anddendritic growth of newly generated neurons in the adult dentate gyrus. Eur. J. Neurosci. 2004, 19:234-246.
44. Verret L., Jankowsky J.L., Xu G.M., Borchelt D.R., Rampon C. Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J. Neurosci. Off. J. Soc. Neurosci. 2007, 27:6771-6780.
45. Wang G. Design, Synthesis and Development of PDE5 Inhibitors 2009, Aston University.
46. Wang J., Jiang Y., Wang Y., Tang Y., Teng G., Fawcett J.P., Kong J., Gu J. A rapid and sensitive LC-MS/MS assay to quantify yonkenafil in rat plasma with application to preclinical pharmacokinetics studies. J. Pharm. Biomed. Anal. 2008, 47:985-989.
47. Wang L., Gang Zhang Z., Lan Zhang R., Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. Off. J. Int. Soc. Cereb. Blood Flow Metab. 2005, 25:1150-1158.
48. Wang L., Zhang Z.G., Zhang R.L., Chopp M. Activation of the PI3-K/Akt pathway mediates cGMP enhanced-neurogenesis in the adult progenitor cells derived from the subventricular zone. J. Cereb. Blood Flow Metab. 2005, 25:1150-1158.
49. Wang Z.X., Tan L., Liu J., Yu J.T. The essential role of soluble Abeta Oligomers in Alzheimer's dis. Mol. Neurobiol. 2015.
50. Wesson D.W., Wilson D.A. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav. Brain Res. 2011, 216:408-413.
51. Wirz K.T.S., Bossers K., Stargardt A., Kamphuis W., Swaab D.F., Hol E.M., Verhaagen J. Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer's disease mouse model. Neurobiol. Aging 2013, 34:1328-1342.
52. Zhang H., Cao H.J., Kimelberg H.K., Zhou M. Volume regulated anion channel currents of rat hippocampal neurons and their contribution to oxygen-and-glucose deprivation induced neuronal death. PloS One 2011, 6:e16803.
53. Zhang J., Guo J., Zhao X., Chen Z., Wang G., Liu A., Wang Q., Zhou W., Xu Y., Wang C. Phosphodiesterase-5 inhibitor sildenafil prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in APP/PS1 transgenic mice. Behav. Brain Res. 2013, 250:230-237.
54. Zhang Q., Yang G., Li W., Fan Z., Sun A., Luo J., Ke Z.-J. Thiamine deficiency increases β-secretase activity and accumulation of β-amyloid peptides. Neurobiol. Aging 2011, 32:42-53.
55. Zhang R.L., Chopp M., Roberts C., Wei M., Wang X., Liu X., Lu M., Zhang Z.G. Sildenafil enhances neurogenesis and oligodendrogenesis in ischemic brain of middle-aged mouse. PloS One 2012, 7:e48141.
56. Zhang W., Hao J., Liu R., Zhang Z., Lei G., Su C., Miao J., Li Z. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav. Brain Res. 2011, 222:342-350.
57. Zhang Y.-w., Thompson R., Zhang H., Xu H. APP processing in Alzheimer's disease. Mol. Brain 2011, 4:3.
58. Zhao S., Yang J., Wang L., Peng S., Yin J., Jia L., Yang X., Yuan Z., Wu C. NF-κB upregulates type 5 phosphodiesterase in N9 microglial cells: inhibition by sildenafil and yonkenafil. Mol. Neurobiol. 2015, 1-12.
59. Zhao S., Zhang L., Lian G., Wang X., Zhang H., Yao X., Yang J., Wu C. Sildenafil attenuates LPS-induced pro-inflammatory responses through down-regulation of intracellular ROS-related MAPK/NF-κB signaling pathways in N9 microglia. Int. Immunopharmacol. 2011, 11:468-474.